Clinical trial
A Phase 2, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of TAK-079 in Patients With Generalized Myasthenia Gravis
NCT04159805 is registered in ClinicalTrials.gov with Takeda as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of TAK-079 in Patients With Generalized Myasthenia Gravis
- Lead sponsor
- Takeda
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- January 14, 2020
- Completion date
- July 12, 2022
- Enrollment
- 36 (actual)
- Sites
- 50
Conditions
As the registry lists them; a condition with its own page is linked.